Results: 10,269 patients received simvastatin and 10,267 patients received placebo. All-cause mortality occurred in 1,328 patients treated with simvastatin and 1,507 patients treated with placebo (p = 0.0003). The risk of death from vascular causes was 5.7% in the simvastatin group and 6.9% in the placebo group (RR 0.83; 95% CI 0.75-0.91). Death from non-vascular causes occurred in 5.3% of simvastatin-treated patients and 5.6% of placebo-treated patients (RR 0.95; CI 0.85-1.07). There were no significant differences in risk of myopathy, liver damage, cancer incidence or hospitalizations for any reason between the two groups.

Based on the results of this trial, how many patients need to be treated with simvastatin for 5 years to prevent one death due to vascular causes?